Phase 3 trial results demonstrate the superiority of long-acting injectable cabotegravir + rilpivirine over daily oral ...
ViiV Healthcare’s long-acting Cabenuva for HIV demonstrates superior efficacy compared to daily oral therapy for people with adherence challenges: London, UK Friday, February 20 ...
The federal Food and Drug Administration has approved Cabenuva, the first complete long-acting injectable HIV regimen that does not require daily pills. It is approved for people with an undetectable ...
Cabenuva is now approved for administration as few as six times a year for virologically suppressed adults living with HIV without prior treatment failure or resistance to cabotegravir or rilpivirine ...
To make Cabenuva the standard treatment option for HIV, Johnson & Johnson and GSK-owned ViiV Healthcare must first dethrone Gilead Sciences’ once-daily stalwart Biktarvy. Now, the partners have a ...
Long-acting cabotegravir/rilpivirine (Cabenuva; CAB/RPV-LA) appeared superior to daily oral antiretroviral therapy (ART) in maintaining viral load suppression for ...
A few weeks ago, Grant Ogren and Rhea Ashby-Durall, the executive director and the outreach manager of SAN (formerly Spokane AIDS Network), met with their representative from Gilead Sciences, the ...
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced final data from the LATITUDE phase III trial, confirming its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results